Comparison of epirubicin and doxorubicin cardiotoxicity in children and adolescents treated within the German Cooperative Soft Tissue Sarcoma Study (CWS)

Journal of Cancer Research and Clinical Oncology

Volumn 132, Issue 1, 2006, Pages 35-40

  Stohr W ^a   Paulides, M ^a   Brecht, I ^b   Kremers, A ^a   Treuner, J ^b   Langer, T ^a   Beck, J D ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b Olgahospital ^*  (Germany)

Author keywords

Cancer; Cardiotoxicity; Doxorubicin; Epirubicin; Sarcoma

Indexed keywords

CARBOPLATIN; DACTINOMYCIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE; VINCRISTINE;

ADOLESCENT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CARDIOMYOPATHY; CARDIOTOXICITY; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART FUNCTION; HEART LEFT VENTRICLE FUNCTION; HIGH RISK PATIENT; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOFT TISSUE SARCOMA; TREATMENT OUTCOME;

ADOLESCENT; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARDIOMYOPATHY, RESTRICTIVE; CHILD; CHILD, PRESCHOOL; DOXORUBICIN; ECHOCARDIOGRAPHY; EPIRUBICIN; FEMALE; HEART; HEART FUNCTION TESTS; HUMANS; INCIDENCE; MALE; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; SARCOMA; VENTRICULAR FUNCTION, LEFT;

EID: 28244475702     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-005-0041-0     Document Type: Article

References (38)

1. Alderton PM, Gross J, Green MD (1992) Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model. Cancer Res 52:194-201
2. Bonadonna G, Gianni L, Santoro A, Bonfante V, Bidoli P, Casali P, Demicheli R,Valagussa P (1993) Drugs ten years later: epirubicin. Ann Oncol 4:359-369
3. Bonneterre J, Roche H, Kerbrat P, Fumoleau P, Goudier MJ, Fargeot P, Montcuquet P, Clavere P, Barats JC, Monnier A, Veyret C, Datchary J, Van Praagh I, Chapelle-Marcillac I (2004) Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group. J Clin Oncol 22:3070-3079
4. Bossi G, Lanzarini L, Laudisa ML, Klersy C, Raisaro A, Arico M (2001) Echocardiographic evaluation of patients cured of childhood cancer: a single centre study of 117 subjects who received anthracyclines. Med Pediatr Oncol 36:593-600
5. Brambilla C, Rossi A, Bonfante V, Ferrari L, Villani F, Crippa F, Bonadonna G (1986) Phase II study of doxorubicin versus epirubicin in advanced breast cancer. Cancer Treat Rep 70:261-266
6. Bu'Lock FA, Mott MG, Oakhill A, Martin RP (1995) Left ventricular diastolic function after anthracycline chemotherapy in childhood: relation with systolic function, symptoms, and pathophysiology. Br Heart J 73:340-350
7. Bu'Lock FA, Mott MG, Oakhill A, Martin RP (1996) Early identification of anthracycline cardiomyopathy: possibilities and implications. Arch Dis Child 75:416-422
8. Cottin Y, Touzery C, Dalloz F, Coudert B, Toubeau M, Riedinger A, Louis P, Wolf JE, Brunotte F (1998) Comparison of epirubicin and doxorubicin cardiotoxicity induced by low doses: evolution of the diastolic and systolic parameters studied by radionuclide angiography. Clin Cardiol 21:665-670
9. Dardir MD, Ferrans VJ, Mikhael YS, el-Grindy MS, el-Aasar AB, el-Zawahry HM, Alling DW, Banks SM, el-Mawla NG (1989) Cardiac morphologic and functional changes induced by epirubicin chemotherapy. J Clin Oncol 7:947-958
10. Gennari A, Salvadori B, Donati S, Bengala C, Orlandini C, Danesi R, Del Tacca M, Bruzzi P, Conte PF (1999) Cardiotoxicity of epirubicin/paclitaxel- containing regimens: role of cardiac risk factors. J Clin Oncol 17:3596-3602
11. Green DM, Grigoriev YA, Nan B, Takashima JR, Norkool PA, D'Angio GJ, Breslow NE (2001) Congestive heart failure after treatment for Wilms' tumor: a report from the National Wilms' Tumor Study group. J Clin Oncol 19:1926-1934
12. Hausdorf G (1993) Late effects of anthracycline therapy in childhood: evaluation and current therapy. In: Bricker JT, Green DM, D'Angio GJE (eds) Cardiac toxicity after treatment for childhood cancer. Wiley-Liss, New York Chichester Brisbane Toronto Singapore, pp 73-85
13. Jain KK, Casper ES, Geller NL, Hakes TB, Kaufman RJ, Currie V, Schwartz W, Cassidy C, Petroni GR, Young CW, et al (1985) A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol 3:818-26
14. Jakacki RI, Larsen RL, Barber G, Heyman S, Fridman M, Silber JH (1993) Comparison of cardiac function tests after anthracycline therapy in childhood. Implications for screening. Cancer 72:2739-2745
15. Kapusta L, Thijssen JM, Groot-Loonen J, Antonius T, Mulder J, Daniels O (2000) Tissue Doppler imaging in detection of myocardial dysfunction in survivors of childhood cancer treated with anthracyclines. Ultrasound Med Biol 26:1099-1108
16. Kremer LC, van Dalen EC, Offringa M, Ottenkamp J, Voute PA (2001) Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J Clin Oncol 19:191-196
17. Kremer LC, van der Pal HJ, Offringa M, van Dalen EC, Voute PA (2002a) Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann Oncol 13:819-829
18. Kremer LCM, van Dalen EC, Offringa M, Voute PA (2002b) Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review. Ann Oncol 13:503-512
19. Lahtinen R, Kuikka J, Nousiainen T, Uusitupa M, Lansimies E (1991) Cardiotoxicity of epirubicin and doxorubicin: a double-blind randomized study. Eur J Haematol 46:301-305
20. Langer T, Henze G, Beck J (2000) Basic methods and the developing structures of a late effects surveillance system (LESS) in the long-term follow-up of pediatric cancer patients in Germany. Med Pediatr Oncol 34:348-351
21. Langer T, Stohr W, Bielack S, Paulussen M, Treuner J, Beck JD (2004) Late effects surveillance system for sarcoma patients. Pediatr Blood Cancer 42:373-379
22. Langer T, Stohr W, Paulides M, Kremers A, Dorr HG, Gobel U, Beck JD (2005) Prospective multicenter registration of major late sequelae in sarcoma patients using the late effects surveillance system (LESS). Klin Padiatr 217:176-181
23. Lanzarini L, Bossi G, Laudisa ML, Klersy C, Arico M (2000) Lack of clinically significant cardiac dysfunction during intermediate dobutamine doses in long-term childhood cancer survivors exposed to anthracyclines. Am Heart J 140:315-323
24. Larsen RL, Jakacki RI, Vetter VL, Meadows AT, Silber JH, Barber G (1992) Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults. Am J Cardiol 70:73-77
25. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP (1991) Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood (see comments). N Engl J Med 324:808-815
26. Lipshultz SE, Easley KA, Orav EJ, Kaplan S, Starc TJ, Bricker JT, Lai WW, Moodie DS, Sopko G, Schluchter MD, Colan SD (2001) Reliability of multicenter pediatric echocardiographic measurements of left ventricular structure and function: the prospective P(2)C(2) HIV study. Circulation 104:310-316
27. Marx M, Langer T, Graf N, Hausdorf G, Stohr W, Ludwig R, Beck JD (2002) Multicentre analysis of anthracycline-induced cardiotoxicity in children following treatment according to the nephroblastoma studies SIOP No. 9/GPOH and SIOP 93-01/GPOH. Med Pediatr Oncol 39:18-24
28. McKillop JH, Bristow MR, Goris ML, Billingham ME, Bockemuehl K (1983) Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity. Am Heart J 106:1048-1056
29. Meinardi MT, van Veldhuisen DJ, Gietema JA, Dolsma WV, Boomsma F, van Den Berg MP, Volkers C, Haaksma J, de Vries EG, Sleijfer DT, van der Graaf WT (2001) Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol 19:2746-2753
30. Nielsen D, Jensen JB, Dombernowsky P, Munck O, Fogh J, Brynjolf I, Havsteen H, Hansen M (1990) Epirubicin cardiotoxicity: a study of 135 patients with advanced breast cancer. J Clin Oncol 8:1806-1810
31. Perez DJ, Harvey VJ, Robinson BA, Atkinson CH, Dady PJ, Kirk AR, Evans BD, Chapman PJ (1991) A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer. J Clin Oncol 9:2148-2152
32. Ryberg M, Nielsen D, Skovsgaard T, Hansen J, Jensen BV, Dombernowsky P (1998) Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J Clin Oncol 16:3502-3508
33. Sorensen K, Levitt G, Bull C, Chessells J, Sullivan I (1997) Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival versus late cardiotoxicity. J Clin Oncol 15:61-68
34. Sorensen K, Levitt G, Sebag-Montefiore D, Bull C, Sullivan I (1995) Cardiac function in Wilms' tumor survivors. J Clin Oncol 13:1546-1556
35. Steinherz L, Wexler L (1998) The prevantion of anthracycline cardiomyopathy. Prog Pediatr Cardiol 8:97-108
36. Steinherz LJ, Graham T, Hurwitz R, Sondheimer HM, Schwartz RG, Shaffer EM, Sandor G, Benson L, Williams R (1992) Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the cardiology committee of the childrens cancer study group. Pediatrics 89:942-949
37. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML (1991) Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 266:1672-1677
38. Torti FM, Bristow MM, Lum BL, Carter SK, Howes AE, Aston DA, Brown BW, Hannigan JF, Meyers FJ, Mitchell EP, et al (1986) Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy. Cancer Res 46:3722-3727